The Limited Times

Now you can see non-English news...

Sanofi recorded strong sales growth in the second quarter

2022-07-28T07:13:58.033Z

The group's revenue climbed 15.7%, beating expectations. The French pharmaceutical giant Sanofi has revised its outlook for 2022 upwards, after a sharp increase in sales in the second quarter, its flagship drug Dupixent continuing to garner sales in various indications. The group's revenues rose by 15.7% (+8.1% at constant exchange rates) to reach 10.1 billion euros, a figure higher than expected by a consensus of analysts polled by Bloomberg. Net prof



The French pharmaceutical giant Sanofi has revised its outlook for 2022 upwards, after a sharp increase in sales in the second quarter, its flagship drug Dupixent continuing to garner sales in various indications.

The group's revenues rose by 15.7% (+8.1% at constant exchange rates) to reach 10.1 billion euros, a figure higher than expected by a consensus of analysts polled by Bloomberg.

Net profit is down slightly to 1.17 billion euros (-1.9%).

Source: lefigaro

All business articles on 2022-07-28

You may like

Life/Entertain 2022-08-03T12:24:23.019Z

Trends 24h

Business 2022-10-04T09:32:18.686Z

Latest

© Communities 2019 - Privacy